Dipeptidyl Peptidase-4 Inhibitor

Known as: DPP-4 Inhibitor 
Any inhibitor of the proline-specific serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. DPP-4 inhibitors bind to DPP-4 and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2003-2017
05010015020032017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
BACKGROUND Dipeptidyl peptidase-4 (DPP-4) inhibitor is a new anti-diabetic drug for type-2 diabetes mellitus patients. Despite… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVES The aim of this study was to investigate the antiatherogenic effects of the dipeptidyl peptidase-4 inhibitor, des… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
AIM This study assessed the influence of various degrees of renal impairment on the exposure of linagliptin, a dipeptidyl… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
OBJECTIVE Vasculoprotective endothelial progenitor cells (EPCs) are regulated by stromal-derived factor-1alpha (SDF-1alpha) and… (More)
  • figure 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on ambulatory blood pressure was assessed in nondiabetic patients… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
OBJECTIVE To assess the efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2… (More)
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
OBJECTIVE Sitagliptin, an oral, potent, and selective dipeptidyl peptidase-4 (DPP-4) inhibitor was evaluated as once-daily… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
AIM To assess the efficacy and safety of a 24-week treatment with sitagliptin, a highly selective once-daily oral dipeptidyl… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The aim of this study was to assess the efficacy and safety of sitagliptin (MK-0431) as monotherapy in patients with type 2… (More)
  • table 1
  • table 1
  • figure 1
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVE The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?